XNAS
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.52 | -0.50 | +3.85% | $0 | ✅ Beat | +0.00% | -17.29% | — |
| 2026-03-26 | Q4 2025 | -0.53 | -0.49 | +7.55% | $0 | ✅ Beat | -2.25% | -1.50% | +49.06% |
| 2025-11-10 |
| Q3 2025 |
| -0.48 |
| -0.37 |
| +22.92% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.54 | -0.37 | +31.48% | $0 | ✅ Beat | -2.17% | +7.97% | +26.81% |
| 2025-03-26 | Q4 2024 | -0.78 | -0.66 | +15.38% | $26.9M | ✅ Beat | +1.70% | -23.01% | -18.75% |
| 2024-11-12 | Q3 2024 | -0.91 | -0.56 | +38.46% | $0 | ✅ Beat | +5.66% | -19.41% | -15.63% |
| 2024-08-09 | Q2 2024 | -0.84 | -1.24 | -47.62% | $0 | ❌ Miss | +0.67% | +4.33% | +1.00% |
| 2024-05-07 | Q1 2024 | -0.77 | 0.14 | +118.18% | $40.6M | ✅ Beat | +0.97% | -5.20% | -9.99% |
Showing last 8 quarters.